Research Topics
Species | M UrosevicSummaryAffiliation: University Hospital Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapyM Urosevic
Department of Dermatology, University Hospital Zurich, Switzerland
Clin Exp Dermatol 30:422-5. 2005..After radiotherapy, immunobiology of BCC may change resulting in the down-regulation of HLA-G expression on tumor and on tumor-infiltrating cells...
Primary cutaneous CD8+ and CD56+ T-cell lymphomas express HLA-G and killer-cell inhibitory ligand, ILT2Mirjana Urosevic
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Blood 103:1796-8. 2004..Together with the expression of IL-10, HLA-G might be one of the factors accounting for the evasion of immunosurveillance, thus contributing to aggressive phenotype of these lymphoma entities...
Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatmentMirjana Urosevic
Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
J Natl Cancer Inst 97:1143-53. 2005..We focused on plasmacytoid predendritic cells (PDCs), the primary producer of interferon alpha (IFN-alpha) after imiquimod activation in vitro...
HLA-G in the skin--friend or foe?Mirjana Urosevic
Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland
Semin Cancer Biol 17:480-4. 2007..This review focuses on the functionality of HLA-G in the skin and summarizes available data obtained from studies performed in skin cancer and inflammatory dermatoses...
Drug evaluation: TG-1042, an adenovirus-mediated IFNgamma gene delivery for the intratumoral therapy of primary cutaneous lymphomasMirjana Urosevic
Address UniversitätsSpital Zürich, Dermatologische Klinik, Gloriastrasse 31, 8091 Zurich Switzerland
Curr Opin Investig Drugs 8:493-8. 2007..A phase I/II clinical trial in CTCL and CBCL was recently completed, and in November 2006 Transgene initiated a phase II clinical trial in CBCL...
HLA-G in skin cancer: a wolf in sheep's clothing?Mirjana Urosevic
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Hum Immunol 64:1073-80. 2003..This review will concentrate on induction and expression of this nonclassical class I molecule in different skin cancer types presenting existing experimental evidence on this topic...
Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomasMirjana Urosevic
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
J Clin Invest 117:2834-46. 2007..Biological effects of type I IFNs seem to enhance those set in motion by the transgene, in our case IFN-gamma. This combination may prove to be of therapeutic importance in cytokine gene transfer using Ads...
HLA-G and IL-10 expression in human cancer--different stories with the same messageMirjana Urosevic
Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, Zurich 8091, Switzerland
Semin Cancer Biol 13:337-42. 2003..This article reviews the current literature on this topic and provides new insights into the role of HLA-G and IL-10 in cancer...
CD4+CD56+ hematodermic neoplasms bear a plasmacytoid dendritic cell phenotypeMirjana Urosevic
Department of Dermatology, University Hospital Zurich, Zurich 8091, Switzerland
Hum Pathol 36:1020-4. 2005..MxA protein, representing the surrogate marker for lesional type I interferon activity, was expressed in 4 of 5 evaluated cases. Our findings further substantiate the putative pDC origin of CD4+CD56+ HNs...
Human leukocyte antigen-G and cancer immunoeditingMirjana Urosevic
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Cancer Res 68:627-30. 2008..In this review, we summarize the evidence that up-regulation of the nonclassic human leukocyte antigen (HLA) class I molecule HLA-G in tumor cells plays an important role in cancer and immune escape...
Expression of melanoma-associated antigens in melanoma cell culturesMirjana Urosevic
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Exp Dermatol 14:491-7. 2005..05-0.001). Elucidation of the MAA expression patterns and the kinetics within the same patient as well as during the course of the disease may help improve current and develop new immunotherapeutic strategies...
Decreased intraindividual HLA class I expression is due to reduced transcription in advanced melanoma and does not correlate with HLA-G expressionJ Willers
Department of Dermatology, University Hospital of Zurich, Switzerland
J Invest Dermatol 117:1498-504. 2001..These data suggest that treatment approaches aimed at activating specific cytotoxic T lymphocytes are most successful in early disease...
Imiquimod in basal cell carcinoma: how does it work?R Dummer
Department of Dermatology, University Hospital of Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
Br J Dermatol 149:57-8. 2003..Our findings demonstrate that imiquimod-induced BCC regression is associated with a strong activity of the innate immune response, mediated by cells of macrophage-monocyte origin and is associated with the induction of apoptosis...
HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomasMirjana Urosevic
Department of Dermatology, University Hospital Zurich, Switzerland
Blood 99:609-17. 2002..001). HLA-G up-regulation together with IL-10 expression in CL might additionally contribute to the evasion of immunosurveillance and facilitate the transition from low- to high-grade lymphomas...
Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha?Mirjana Urosevic
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Clin Cancer Res 10:4959-70. 2004..Our data add to the growing list of basal cell carcinoma-associated tumor antigens...
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 productionM Urosevic
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Am J Pathol 159:817-24. 2001..It is conceivable that HLA-G expression in lung cancer might be one of the ways how the tumor down-regulates host immune response, in addition to interleukin-10 production and HLA class I loss...
Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patientsKarin Murer
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Melanoma Res 14:257-62. 2004..0038). This could not be shown for any of the markers tested by FACS. Our results suggest that the expression of Melan-A/MART-1 in patient-derived cell cultures may help to identify a group of melanoma patients with prolonged survival...
Role of imiquimod in skin cancer treatmentMirjana Urosevic
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Am J Clin Dermatol 5:453-8. 2004..This article reviews current literature on the use of imiquimod in the treatment of nonmelanoma and melanoma skin cancer...
Pathogenesis of cutaneous lymphomasR Dummer
Department of Dermatology, University of Zurich Medical School, Switzerland
Semin Cutan Med Surg 19:78-86. 2000..Newly identified molecular disturbances in cutaneous lymphomas might be targeted by specific molecular or immunologic interventions in the future...
Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivoMirjana Urosevic
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Arch Dermatol 139:1325-32. 2003..Interleukin 10 was produced by infiltrating cells but was not produced by tumor cells. Tumor expression of TAP-1 and Fas/FasL appeared to be unaffected in the first 5 days of treatment...
Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patientsSenta M Walton
Medical Oncology, Department of Internal Medicine, University Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland
J Immunol 177:8212-8. 2006..In addition to the identification of a RAB38/NY-MEL-1-derived immunogenic CD8 T cell epitope, this study is instrumental for both the onset and monitoring of future RAB38/NY-MEL-1-based vaccination trials...
Real-time polymerase chain reaction monitoring of epithelial cell adhesion molecule-induced T-cell stimulation in patients with lung cancer and healthy individuals using LightCycler technologyAndreas Trojan
Division of Oncology, Department of Internal Medicine, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
J Immunother 25:264-8. 2002..Our study indicates that quantitative polymerase chain reaction may be a supplement to chromium-release assay for monitoring in vitro expanded CTL precursor reactivity...
Immunotherapy for nonmelanoma skin cancer: does it have a future?Mirjana Urosevic
Department of Dermatology, University Hospital Zurich, Switzerland
Cancer 94:477-85. 2002..CONCLUSIONS: In addition to clinical cure, by activating and stimulating patient's immune resources this therapeutic option may be a "silver bullet," providing a long-term protective immunity against initial tumor...
Induction of the members of Notch pathway in superficial basal cell carcinomas treated with imiquimodMaja Wuest
Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, Zurich, Switzerland
Arch Dermatol Res 299:493-8. 2007..Via induction of Notch signaling imiquimod may exert tumor suppressor function, which together with its proinflammatory properties results in tumor regression...
Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomasReinhard Dummer
Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich, Switzerland
Blood 104:1631-8. 2004..We demonstrate the induction of humoral immune response to lymphoma tumor-antigen se70-2 after treatment. Our study shows that intralesional injections of TG1042 are both safe and well tolerated...
[Perspective of cutaneous lymphoma reserach]Reinhard Dummer
Dermatologische Klinik, Universitatsspital Zurich, Schweiz
J Dtsch Dermatol Ges 4:492-5. 2006..The new WHO/EORTC classification definitely will facilitate a more detailed investigation of the various subtypes...
Recent advances in cutaneous lymphomasReinhard Dummer
Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, CH 8091 Zurich, Switzerland
J Dermatol Sci 48:157-67. 2007....
An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanomaReinhard Dummer
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Clin Cancer Res 14:856-64. 2008..A topical Toll-like receptor 7 (TLR7) agonist induces regression of cutaneous melanocytic neoplasms. We explored antitumor activity of a systemically administered TLR7 agonist, 852A, in patients with metastatic melanoma...
Intralesional adenovirus-mediated interleukin-2 gene transfer for advanced solid cancers and melanomaReinhard Dummer
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Mol Ther 16:985-94. 2008..Our results show that intratumoral injections of TG1024 are safe and well tolerated. The clinical activity of TG1024 observed in this study warrants further investigations...
Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patientsAlfred Zippelius
Klinik und Poliklinik für Onkologie, Departement fur Innere Medizin, Universitatsspital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
Cancer Immunol Immunother 56:249-58. 2007..Implications for the understanding of spontaneous humoral immune responses are discussed...
Pathogenesis and therapy of cutaneous lymphomas--progress or impasse?Reinhard Dummer
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Exp Dermatol 15:392-400. 2006....
Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomographyPatrick A Oberholzer
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Dermatology 217:351-5. 2008..Baseline staging is important in all melanoma types, including melanoma with unknown primary site (MUP). Staging includes different examination strategies, each with different accuracy...
Immune activation status of CD8+ T cells infiltrating non-small cell lung cancerAndreas Trojan
Department of Oncology, University Hospital Zurich, Ramistrasse 100, CH 8091 Zurich, Switzerland
Lung Cancer 44:143-7. 2004..Our results indicate that CD8+ T cells infiltrating the tumor cell nests may be inadequately activated and thus incapable of mounting an effective anti-tumor immune response...
Standard and experimental therapy in cutaneous T-cell lymphomasReinhard Dummer
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
J Cutan Pathol 33:52-7. 2006..Evidence-based treatment recommendation exists but is hampered by the lack of large multicenter randomized trials...
Successful imiquimod treatment of multiple basal cell carcinomas after radiation therapy for Hodgkin's diseaseMirjam Beyeler
Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zurich Switzerland
Eur J Dermatol 15:52-5. 2005..Until now he is in complete remission. However, multiple superficial basal cell carcinomas have developed on irradiation fields that have been successfully treated by imiquimod...
Superficial radiotherapy for patients with basal cell carcinoma: recurrence rates, histologic subtypes, and expression of p53 and Bcl-2Beate Zagrodnik
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Cancer 98:2708-14. 2003..Expression analyses confirmed that p53 and Bcl-2 levels may be used as indicators for the aggressiveness of a BCC subtype. Due to the high incidence of additional skin malignancies, patients with BCC need careful follow-up...
Exploring primary cutaneous B-cell lymphoma by microarray technologyReinhard Dummer
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
J Invest Dermatol 120:vii-viii. 2003
Imiquimod induces complete clearance of a PUVA-resistant plaque in mycosis fungoidesReinhard Dummer
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
Dermatology 207:116-8. 2003..However, the plaque on the face was PUVA resistant. Local imiquimod treatment resulted in the complete clearance of the plaque. The patient has now been in complete remission for 12 months...
The interferon inhibiting cytokine IK is overexpressed in cutaneous T cell lymphoma derived tumor cells that fail to upregulate major histocompatibility complex class II upon interferon-gamma stimulationJ Willers
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
J Invest Dermatol 116:874-9. 2001..Interferon inhibiting cytokine factor may participate in providing a microenvironment at the tumor site insensitive to interferon-gamma stimulation and thus prevents an efficient local immune response...
Green tea extract reduces induction of p53 and apoptosis in UVB-irradiated human skin independent of transcriptional controlsChristian D Mnich
Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland
Exp Dermatol 18:69-77. 2009..Topical GTE (OM24) reduces UVB-mediated epithelial damage already at low, cosmetically usable concentrations, without tachyphylaxis over 5 weeks, suggesting GTE as suitable everyday photochemopreventive agents...
HLA-G and its KIR ligands in cancer--another enigma yet to be solved?Mirjana Urosevic
J Pathol 196:252-3. 2002..Moreover, a subset of infiltrating cells also expressed HLA-G-recognizing KIR, ILT-2. This editorial discusses the induction of HLA-G and related KIR molecules as another mechanism for tumours to escape immune recognition...
Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCRAndreas Trojan
Division of Oncology, Department of Internal Medicine, University Hospital Zurich, Ramistrasse 100, 8091 Zurich, Switzerland
J Immunother 26:41-6. 2003..Results from this study indicate that the use of bioinformatics and the PCR-based screening system for the monitoring of T cell reactivity may allow for the identification of novel CTL epitopes...
Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiationSibylla Martinelli
Department of Pharmacology, University of Bern, CH-3010, Switzerland
J Biol Chem 279:44123-32. 2004..These data contribute to our understanding regarding changes of gene expression during neutrophil differentiation and IFN-mediated anti-bacterial defense mechanisms...
